| Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma S Kakadia, N Yarlagadda, R Awad, M Kundranda, J Niu, B Naraev, ... OncoTargets and therapy, 7095-7107, 2018 | 241 | 2018 |
| High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience M Hanzly, A Aboumohamed, N Yarlagadda, T Creighton, L Digiorgio, ... Urology 83 (5), 1129-1134, 2014 | 44 | 2014 |
| Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns C Schinke, EM Boyle, C Ashby, Y Wang, V Lyzogubov, C Wardell, P Qu, ... Blood cancer journal 10 (6), 70, 2020 | 33 | 2020 |
| Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma M Mohan, S Kendrick, A Szabo, N Yarlagadda, D Atwal, Y Pandey, A Roy, ... Blood Advances 6 (3), 808-817, 2022 | 19 | 2022 |
| Immunotherapy outcomes in advanced melanoma in relation to age K Joshi, D Atwal, R Ravilla, Y Pandey, N Yarlagadda, S Kakadia, ... The Permanente Journal 24, 2020 | 10 | 2020 |
| Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther … S Kakadia, N Yarlagadda, R Awad, M Kundranda, J Niu, B Naraev, ... S182721.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 8 | |
| Hemophagocytic lymphohistiocytosis in adults Y Pandey, D Atwal, M Konda, M Bimali, D Middleton, N Yarlagadda, ... Baylor University Medical Center Proceedings 33 (3), 326-330, 2020 | 7 | 2020 |
| Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma MZ Meera Mohan, Aniko Szabo, Naveen Yarlagadda, Sravani Gundarlapalli ... American Journal of Hematology, 2021 | 5 | 2021 |
| Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma. M Mohan, NK Yarlagadda, D Atwal, Y Pandey, A Roy, R Parikh, J Lopez, ... Journal of Clinical Oncology 38 (15_suppl), 8514-8514, 2020 | 3 | 2020 |
| The mutational landscape of primary plasma cell leukemia CD Schinke, C Ashby, Y Wang, RG Tytarenko, E Boyle, C Wardell, P Qu, ... Blood 132, 114, 2018 | 3 | 2018 |
| Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer N Batty, N Yarlagadda, R Pili Journal of the National Comprehensive Cancer Network 11 (8), 911-915, 2013 | 3 | 2013 |
| Clinical characteristics of testicular extramedullary involvement in multiple myeloma CS Meera Mohan, Naveen Yarlagadda, Aniko Szabo, Amrit Singh, Sergio Pina Oviedo American Journal of Hematology 96 (3), E77-E81, 0 | 3* | |
| Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. N Yarlagadda, S Gundarlapalli, S Sharma, E Suelzer, MB Abid, ... Leukemia Research 110, 106714-106714, 2021 | 2 | 2021 |
| Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma J Lopez, N Yarlagadda, Z Gheith, M Mohan, A Sasapu Baylor University Medical Center Proceedings 33 (1), 59-61, 2020 | 1 | 2020 |
| Survey of Compliance to Infection Control Measures and Its Impact on Healthcare of Patients in a Hematopoietic Stem Cell Transplant Unit N Yarlagadda, G Krishnan, M Mohan, A Johnsrud, F Wolfe, A Kothari Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 1 | 2018 |
| Sleep-wake Disturbance following Allogeneic Hematopoietic Stem Cell Transplantation: Trajectory and Correlates M VEERAPUTHIRAN, J Gernat, N Yarlagadda, M Bimali, EE Matthews | | 2022 |
| Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma M Mohan, S Gundarlapalli, A Szabo, N Yarlagadda, S Kakadia, M Konda, ... American journal of hematology 97 (6), E195-E198, 2022 | | 2022 |
| Tandem Autologous Stem Cell Transplantation in Patients with Persistent Bone Marrow Minimal Residual Disease Post First Transplantation in Multiple Myeloma. M Mohan, S Gundarlapalli, A Szabo, N Yarlagadda, A Jillella, M Konda, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance NK Yarlagadda, M Mohan, S Atrash, S Gundarlapalli, S Hoque, S Kakadia, ... Blood 138, 2713, 2021 | | 2021 |
| TREATMENT STRATEGIES, OUTCOMES OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA A Roy, R Parikh, Y Pandey, N Yarlagadda, A Sasapu JOURNAL OF INVESTIGATIVE MEDICINE 69 (2), 571-572, 2021 | | 2021 |
Meera MohanMedical College of WisconsinVerified email at mcw.edu
